ArticleDrug design, development and therapy2025
A Comparison of in-vitro Pharmacokinetics and Pharmacodynamics of Branded and Its Locally Produced Cefuroxime Sodium Against
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent Gaps in the Ultimate Mechanisms of Antimicrobial-Induced Bacterial Killing.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the in-vitro antibacterial effects of branded and its locally produced cefuroxime sodium against Methods: An in-vitro antibacterial susceptibility test, time-kill curve and pharmacokinetics and pharmacodynamics (PK/PD) modeling was used in the comparison. Results: The minimum inhibitory concentrations (MIC) of the two types of cefuroxime sodium were identical against four bacterial strains; both types of cefuroxime sodium had MICs of 0.5 μg/mL, 8 μg/mL, 0.5 μg/mL, and 0.25 μg/mL against ATCC 29213, ATCC 25922, M164342 and MSCNS117933, respectively. There were no significant differences in the time-kill curves of the two forms against the four strains at three concentrations. At drug concentrations of 2×MIC and 4×MIC, the bacterial count of all the strains decreased from 6 log CFU/mL to around 4 log CFU/mL. The bactericidal efficacies of the two agents were generally similar in the pharmacokinetics model of simulated intravenous drug administration of 1 g q8h. Only the PD parameter of bactericidal rate (KR) for ATCC 29213 and the area difference between the drug bactericidal curve and the bacterial growth control curve (I Conclusion: The in-vitro antibacterial effect of locally produced cefuroxime sodium against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.